Could this 60-year-old man with necrotising fasciitis, candidemia, severe inflammation, acute kidney injury, anemia, thrombocytopenia, and low reticulocyte production index have secondary hemophagocytic lymphohistiocytosis (HLH)?

Yes, secondary HLH should be strongly considered in this clinical scenario

This 60-year-old man with necrotizing fasciitis, candidemia, severe inflammation, acute kidney injury, anemia, thrombocytopenia, and low reticulocyte production index presents a classic constellation of findings that warrants immediate evaluation for infection-associated secondary HLH.

Why Secondary HLH is Likely Here

The patient demonstrates multiple overlapping features of both severe sepsis and HLH, which is precisely the diagnostic challenge emphasized in recent guidelines 1. Infection is one of the two most common triggers for secondary HLH in adults 1, and the combination of severe bacterial infection (necrotizing fasciitis) with fungal infection (candidemia) creates a particularly high-risk scenario for triggering pathological hyperinflammation.

Key Clinical Features Supporting HLH

The patient's presentation includes several cardinal features:

• Cytopenias: Anemia and thrombocytopenia with low reticulocyte production index suggests bone marrow involvement rather than simple consumption
• Severe inflammation: The hyperinflammatory state goes beyond typical sepsis
• Acute kidney injury: Renal involvement is frequently encountered in HLH and can result from systemic inflammatory mediators, direct damage, or macrophage infiltration 2
• Dual severe infections: Both necrotizing fasciitis and candidemia represent the type of overwhelming infectious triggers that commonly precipitate secondary HLH 1

The Sepsis-HLH Diagnostic Dilemma

The most critical pitfall here is that secondary HLH and sepsis share remarkably similar presentations, making differentiation extremely challenging 3, 2. Both conditions present with prolonged fever, hepatosplenomegaly, cytopenias, hepatic dysfunction, and systemic inflammatory response 2. However, this overlap does not exclude HLH—in fact, many patients with HLH arising during severe infection have concomitant sepsis 1.

Distinguishing Features to Evaluate Immediately

Look for these specific markers that favor HLH over sepsis alone:

• Ferritin levels: Marked hyperferritinemia (ideally >10,000 µg/L) is highly suggestive 4
• Triglycerides: Hypertriglyceridemia is a distinctive feature 2
• Fibrinogen: Hypofibrinogenemia (distinct from DIC pattern) 2
• Soluble IL-2 receptor alpha (sCD25): Elevated levels help differentiate HLH from sepsis 2
• Dual hemocytopenia: The combination of anemia and thrombocytopenia with low reticulocyte production suggests marrow involvement 2

Diagnostic Approach

Calculate the HScore immediately using available clinical and laboratory data. An HScore >169 corresponds to >93% probability of HLH, and >250 indicates >99% probability 5, 4. The HScore incorporates:

• Known immunosuppression
• Temperature
• Organomegaly
• Cytopenias (number of lineages affected)
• Ferritin level
• Triglycerides
• Fibrinogen
• AST
• Hemophagocytosis on bone marrow (if performed)

Bone marrow aspiration should be pursued urgently if HScore is elevated or clinical suspicion remains high, as demonstration of hemophagocytosis significantly increases diagnostic certainty 6, 5, 4.

Critical Management Considerations

The treatment paradigms for sepsis versus HLH diverge dramatically 2:

• Sepsis: Anti-infective therapy and supportive care
• HLH: Immunosuppression (corticosteroids, potentially etoposide, anakinra, or tocilizumab)

The key danger is that patients can die of aggressive HLH while receiving infection-directed therapy alone 1. However, initiating immunosuppression in pure sepsis without HLH could be catastrophic.

Treatment Algorithm if HLH is Confirmed

1. Continue aggressive infection control: Antibiotics/antifungals must be maintained regardless 1
2. Initiate corticosteroids: High-dose dexamethasone or methylprednisolone as first-line therapy 6, 7, 5
3. Consider additional immunomodulation: Anakinra or tocilizumab for refractory cases 7, 5
4. Monitor renal function closely: Adjust chemotherapy and antibiotic dosing based on kidney function, as this profoundly impacts prognosis 2

Prognostic Considerations

Infection-associated secondary HLH carries significant mortality risk, but outcomes improve dramatically with early recognition and treatment 6, 5. The presence of acute kidney injury complicates both diagnosis and treatment but does not preclude recovery if HLH-directed therapy is initiated promptly 2, 8. Cases in the literature demonstrate that patients can achieve full recovery when the underlying trigger is addressed alongside immunosuppression 6, 7, 5.

Common Pitfalls to Avoid

• Assuming all inflammation is sepsis-related: The non-specific presentation leads to diagnostic delay 4
• Waiting for fever: HLH can present without fever, particularly in immunosuppressed patients 7
• Delaying bone marrow biopsy: This is the definitive diagnostic test and should not be postponed 6, 5, 4
• Treating infection alone: Some patients deteriorate despite appropriate antibiotics, signaling underlying HLH 6
• Missing the therapeutic window: Timely diagnosis creates an opportunity to reverse organ dysfunction and improve prognosis 2

In this specific case, the combination of dual severe infections, cytopenias with low reticulocyte production, acute kidney injury, and severe inflammation creates a high pretest probability for secondary HLH that mandates immediate diagnostic evaluation with ferritin, triglycerides, fibrinogen, sCD25, HScore calculation, and consideration of urgent bone marrow examination.